

## National Institutes of Health Update

---

Claire Schuster, MPH  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

March 2021




National Institute of Allergy and Infectious Diseases

1


### Phase 2 Clinical Trial Begins: Testing Bexsero as a Gonorrhea Vaccine

---

- **2015:** FDA licensed Bexsero vaccine to prevent Group B meningitis (Novartis/GSK)
- **2017:** New Zealand study found effectiveness of Group B meningitis vaccine against gonorrhea
  - Vaccinated people were less likely to contract gonorrhea. (<https://www.ncbi.nlm.nih.gov/pubmed/28705462>)
- **2020:** NIAID-supported Phase 2 clinical trial began in late 2020
  - In collaboration with NIAID-supported STI Clinical Trials Group, GSK, & Uniformed Services University of Health Sciences (USUHS)
  - Objective: To demonstrate efficacy of Bexsero in prevention of gonococcal infection
  - <https://clinicaltrials.gov/ct2/show/NCT04350138>

Adapted from E. Erbeling/NIAID

2



3

### COVID-19 Vaccines in Operation Warp Speed Development

**moderna** mRNA

**BIONTECH** mRNA

**AstraZeneca** Adenovirus vector

**Janssen** Adenovirus vector

**NOVAVAX** Recombinant protein + adjuvant

**gsk SANOFI** Recombinant protein + adjuvant

- **mRNA:** rapid manufacturing facilitating efficient move to clinic, highly immunogenic
- **Adenovirus:** rapid manufacturing facilitating efficient move to clinic, vaccine using this platform is approved in Europe
- **Adjuvanted recombinant protein:** not as fast to manufacture but scalable, several approved vaccines use this approach

4

### Pediatric COVID-19 Vaccines

February 12, 2021

The New York Times

Covid Vaccines for Kids Are Coming, but Not for Many Months

A. Mandavilli

February 26, 2021

Science

Vaccine trials ramp up in children and adolescents

J. Couzin-Frankel

5

### Multisystem Inflammatory Syndrome in Children (MIS-C)

---

- NIH launches Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM)
  - **Purpose:** To evaluate short- and long-term health outcomes of SARS-CoV-2 infection in children, including MIS-C
  - **Participants:** At least 250 children and young adults ages 20 years or younger from diverse racial and ethnic backgrounds
  - **Locations:** Approximately 20 sites nationwide
- NIH funds eight studies to uncover risk factors for MIS-C
  - **Purpose:** To explore how genetic, immune, viral, environmental, and other factors influence the severity of COVID-19 in children and the chances of progression to MIS-C and other long-term complications
  - **Participants:** Children with diverse geographic, racial and ethnic backgrounds
  - **Locations:** 30 U.S. States, Canada, the U.K. and South America

6

## COVID-19 Research and Pregnancy



**NIH News**  
National Institutes of Health

U.S. Department of Health and Human Services

**Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)**  
<https://www.nichd.nih.gov>  
February 17, 2021

**NIH funds study to evaluate remdesivir for COVID-19 in pregnancy**



Credit: NIAD

7




**NIH News**  
National Institutes of Health

National Institute of Allergy and Infectious Diseases (NIAID)  
<http://www.niaid.nih.gov>  
December 11, 2020

### Baricitinib Plus Remdesivir Shows Promise for Treating COVID-19

*Peer-Reviewed Results of NIH Clinical Trial Published*

Kalil et al. Baricitinib plus remdesivir for the treatment of hospitalized adults with Covid-19. A randomized double-blind placebo-controlled trial. *New England Journal of Medicine* (2020 Dec 11)



Credit: NIAID

8

## NIH Director's Blog

### Trying to Make Sense of Long COVID Syndrome

Posted on January 19th, 2021 by Dr. Francis Collins



Credit: NIH

9

### New Online Resource Shows How You Can Help to Fight COVID-19

Posted on December 15th, 2020 by Dr. Francis Collins

## COVID-19 AND YOU

Information to help you make decisions about your health and what you can do to join the fight against COVID-19.

[combatcovid.hhs.gov](http://combatcovid.hhs.gov)



10